GlassScriptPhysician profile
Steven A Meckstroth
NPI 1073508123
$8,780.27
in general payments reported to CMS, 2019-2025
28 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $374 · 2021: $1,292 · 2022: $1,648 · 2023: $1,528 · 2024: $1,224 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,824.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,457.09 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $917.33 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $635.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.25 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $295.18 | 2022-2025 | Axonics, Compliance Endokit, Cre Pro |
| Mauna Kea Technologies, INC. | $294.09 | 2022-2025 | |
| Redhill Biopharma INC. | $264.46 | 2020-2023 | |
| Celgene Corporation | $222.71 | 2021-2023 | Zeposia |
| Axonics, INC. | $185.07 | 2023-2024 | Axonics |
| Vivus LLC | $154.32 | 2022-2025 | Qsymia, Pancreaze |
| Pfizer INC. | $146.15 | 2022-2025 | |
| Allergan, INC. | $110.49 | 2019 | |
| Madrigal Pharmaceuticals | $100.83 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $82.34 | 2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $81.54 | 2019 | |
| Merck Sharp & Dohme LLC | $77.00 | 2019-2023 | Dificid, Zinplava |
| Shionogi INC | $72.52 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $71.25 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $60.19 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $56.35 | 2023-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $53.73 | 2025 | Voquezna |
| Shire North American Group INC | $48.33 | 2019 | |
| Novo Nordisk INC | $46.17 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $24.83 | 2022 | |
| Ardelyx, INC. | $22.17 | 2022 | |
| Lilly USA, LLC | $17.67 | 2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Meckstroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.